Skip to main content
Erschienen in: Der Gynäkologe 12/2015

01.12.2015 | Endokrinologie und Reproduktionsmedizin | CME

Hyperandrogenämie – Diagnostik und Therapiekonzepte

verfasst von: Prof. Dr. Christoph Keck, PD Dr. Sabine Elisabeth Segerer

Erschienen in: Die Gynäkologie | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei erhöhten Androgenspiegeln im Blut wird von Hyperandrogenämie gesprochen, bei einer verstärkten peripheren Androgenwirkung (auch wenn die Androgenspiegel im Referenzbereich liegen) von Hyperandrogenismus. Zur differenzialdiagnostischen Basisabklärung werden Androstendion, Dehydroepiandrosteronsulfat und Testosteron im Serum bestimmt. Zur weiterführenden Diagnostik zählen die Dihydrotestosteronmessung, ACTH- und Dexamethasontests sowie die molekulargenetische Analyse potenzieller Enzymdefekte der Steroidgenese. Ursächlich sind das polyzystische Ovarsyndrom, der „idiopathische Hyperandrogenismus“, das late-onset adrenogenitale Syndrom, androgenproduzierende Tumoren und die exogene Zufuhr von Androgenen/Steroiden. Die Behandlung richtet sich nach der Ursache, aber auch nach der Lebenssituation (z. B. Familienplanung). Bei ausgeprägter kutaner Manifestation empfiehlt sich die Kooperation mit dem Dermatologen, um eine individualisierte Therapie anzubieten.
Literatur
1.
Zurück zum Zitat Labrie F, Luu-The V, Lin SX, Simard J, Labrie C et al (2000) Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol 25:1–16CrossRefPubMed Labrie F, Luu-The V, Lin SX, Simard J, Labrie C et al (2000) Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol 25:1–16CrossRefPubMed
2.
Zurück zum Zitat Labrie F, Luu-The V, Lin SX, Simard J, Labrie C (2000) Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol Metab 11:421–427CrossRefPubMed Labrie F, Luu-The V, Lin SX, Simard J, Labrie C (2000) Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol Metab 11:421–427CrossRefPubMed
3.
Zurück zum Zitat Voutilainen R, Jaaskelainen J (2015) Premature adrenarche: etiology, clinical findings, and consequences. J Steroid Biochem Mol Biol 145:226–236CrossRefPubMed Voutilainen R, Jaaskelainen J (2015) Premature adrenarche: etiology, clinical findings, and consequences. J Steroid Biochem Mol Biol 145:226–236CrossRefPubMed
4.
Zurück zum Zitat Utriainen P, Laakso S, Liimatta J, Jaaskelainen J, Voutilainen R (2015) Premature adrenarche – a common condition with variable presentation. Horm Res Paediatr 83:221–231CrossRefPubMed Utriainen P, Laakso S, Liimatta J, Jaaskelainen J, Voutilainen R (2015) Premature adrenarche – a common condition with variable presentation. Horm Res Paediatr 83:221–231CrossRefPubMed
5.
Zurück zum Zitat Kley HK, Nieschlag E, Wiegelmann W, Solbach HG, Kruskemper HL (1975) Steroid hormones and their binding in plasma of male patients with fatty liver, chronic hepatitis and liver cirrhosis. Acta Endocrinol (Copenh) 79:275–285 Kley HK, Nieschlag E, Wiegelmann W, Solbach HG, Kruskemper HL (1975) Steroid hormones and their binding in plasma of male patients with fatty liver, chronic hepatitis and liver cirrhosis. Acta Endocrinol (Copenh) 79:275–285
6.
Zurück zum Zitat Schmidt TH, Shinkai K (2015) Evidence-based approach to cutaneous hyperandrogenism in women. J Am Acad Dermatol 73:672–690CrossRefPubMed Schmidt TH, Shinkai K (2015) Evidence-based approach to cutaneous hyperandrogenism in women. J Am Acad Dermatol 73:672–690CrossRefPubMed
7.
Zurück zum Zitat Carmina E, Rosato F, Janni A, Rizzo M, Longo RA (2006) Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 91:2–6CrossRefPubMed Carmina E, Rosato F, Janni A, Rizzo M, Longo RA (2006) Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 91:2–6CrossRefPubMed
8.
Zurück zum Zitat Markopoulos MC, Kassi E, Alexandraki KI, Mastorakos G, Kaltsas G (2015) Hyperandrogenism after menopause. Eur J Endocrinol 172:R79–R91CrossRefPubMed Markopoulos MC, Kassi E, Alexandraki KI, Mastorakos G, Kaltsas G (2015) Hyperandrogenism after menopause. Eur J Endocrinol 172:R79–R91CrossRefPubMed
9.
Zurück zum Zitat Cordera F, Grant C, van Heerden J, Thompson G, Young W (2003) Androgen-secreting adrenal tumors. Surgery 134:874–880 (discussion 880)CrossRefPubMed Cordera F, Grant C, van Heerden J, Thompson G, Young W (2003) Androgen-secreting adrenal tumors. Surgery 134:874–880 (discussion 880)CrossRefPubMed
10.
Zurück zum Zitat Azziz R (2006) Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 91:781–785CrossRefPubMed Azziz R (2006) Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 91:781–785CrossRefPubMed
11.
Zurück zum Zitat Franks S (2006) Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 91:786–789CrossRefPubMed Franks S (2006) Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 91:786–789CrossRefPubMed
12.
Zurück zum Zitat Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47CrossRef Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47CrossRef
14.
Zurück zum Zitat Rosenfield RL (1999) Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 28:265–293CrossRefPubMed Rosenfield RL (1999) Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 28:265–293CrossRefPubMed
15.
Zurück zum Zitat Jonard S, Dewailly D (2004) The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 10:107–117CrossRefPubMed Jonard S, Dewailly D (2004) The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 10:107–117CrossRefPubMed
16.
Zurück zum Zitat Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM et al (2001) The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 86:5925–5933CrossRefPubMed Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM et al (2001) The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 86:5925–5933CrossRefPubMed
17.
18.
Zurück zum Zitat Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH et al (2013) Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 98:4565–4592CrossRefPubMed Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH et al (2013) Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 98:4565–4592CrossRefPubMed
19.
Zurück zum Zitat Catteau-Jonard S, Dewailly D (2013) Pathophysiology of polycystic ovary syndrome: the role of hyperandrogenism. Front Horm Res 40:22–27CrossRefPubMed Catteau-Jonard S, Dewailly D (2013) Pathophysiology of polycystic ovary syndrome: the role of hyperandrogenism. Front Horm Res 40:22–27CrossRefPubMed
20.
Zurück zum Zitat Pillay OC, Te Fong LF, Crow JC, Benjamin E, Mould T et al (2006) The association between polycystic ovaries and endometrial cancer. Hum Reprod 21:924–929CrossRefPubMed Pillay OC, Te Fong LF, Crow JC, Benjamin E, Mould T et al (2006) The association between polycystic ovaries and endometrial cancer. Hum Reprod 21:924–929CrossRefPubMed
21.
Zurück zum Zitat Giudice LC (2006) Endometrium in PCOS: Implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab 20:235–244CrossRefPubMed Giudice LC (2006) Endometrium in PCOS: Implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab 20:235–244CrossRefPubMed
22.
Zurück zum Zitat Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA et al (2008) Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1105–1120CrossRefPubMed Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA et al (2008) Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1105–1120CrossRefPubMed
23.
Zurück zum Zitat Ferriman D, Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440–1447CrossRefPubMed Ferriman D, Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440–1447CrossRefPubMed
24.
Zurück zum Zitat Van der Spuy ZM, le Roux PA (2003) Cyproterone acetate for hirsutism. Cochrane Database Syst Rev. doi:10.1002/14651858.CD001125PubMed Van der Spuy ZM, le Roux PA (2003) Cyproterone acetate for hirsutism. Cochrane Database Syst Rev. doi:10.1002/14651858.CD001125PubMed
25.
Zurück zum Zitat Swiglo BA, Cosma M, Flynn DN, Kurtz DM, Labella ML et al (2008) Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 93:1153–1160CrossRefPubMed Swiglo BA, Cosma M, Flynn DN, Kurtz DM, Labella ML et al (2008) Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 93:1153–1160CrossRefPubMed
26.
27.
Zurück zum Zitat Townsend KA, Marlowe KF (2004) Relative safety and efficacy of finasteride for treatment of hirsutism. Ann Pharmacother 38:1070–1073CrossRefPubMed Townsend KA, Marlowe KF (2004) Relative safety and efficacy of finasteride for treatment of hirsutism. Ann Pharmacother 38:1070–1073CrossRefPubMed
28.
Zurück zum Zitat Moghetti P, Tosi F, Tosti A, Negri C, Misciali C et al (2000) Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 85:89–94PubMed Moghetti P, Tosi F, Tosti A, Negri C, Misciali C et al (2000) Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 85:89–94PubMed
29.
Zurück zum Zitat Sreekumar GP, Pardinas J, Wong CQ, Whiting D, Katz HI et al (1999) Serum androgens and genetic linkage analysis in early onset androgenetic alopecia. J Investig Dermatol 113:277–279CrossRefPubMed Sreekumar GP, Pardinas J, Wong CQ, Whiting D, Katz HI et al (1999) Serum androgens and genetic linkage analysis in early onset androgenetic alopecia. J Investig Dermatol 113:277–279CrossRefPubMed
30.
31.
Zurück zum Zitat Sinclair R, Wewerinke M, Jolley D (2005) Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 152:466–473CrossRefPubMed Sinclair R, Wewerinke M, Jolley D (2005) Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 152:466–473CrossRefPubMed
32.
Zurück zum Zitat Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM et al (2014) The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol 80:521–525CrossRefPubMed Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM et al (2014) The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol 80:521–525CrossRefPubMed
Metadaten
Titel
Hyperandrogenämie – Diagnostik und Therapiekonzepte
verfasst von
Prof. Dr. Christoph Keck
PD Dr. Sabine Elisabeth Segerer
Publikationsdatum
01.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Gynäkologie / Ausgabe 12/2015
Print ISSN: 2731-7102
Elektronische ISSN: 2731-7110
DOI
https://doi.org/10.1007/s00129-015-3807-8

Weitere Artikel der Ausgabe 12/2015

Der Gynäkologe 12/2015 Zur Ausgabe

Medizinrecht

Medizinrecht

Update Gynäkologie Pränataldiagnostik

Update Gynäkologie Pränataldiagnostik